Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Axsome Therapeutics

uniQure

Voyager Therapeutics

Reviva Pharmaceuticals

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session.

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today

In recent years, gene therapy and gene editing are growing in prominence. Leading the gene-editing innovation, CRISPR Therapeutics is poised to make history in this space. The latest data for the sickle cell disease and beta-thalassemia franchises are extremely robust.

Crispr Therapeutics: Strong Partnership And Data Development

BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) --  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 was previously granted PRIME designation for the treatment of sickle cell disease (SCD) in 2020.

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia

On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

Shopify

Both of these stocks have struggled in recent weeks, which means it might be a good time to initiate a position.

2 Unstoppable Cathie Wood Stocks That Could Make You Rich

Crispr Therapeutics: Pipeline Catalyst Triggering Upside

KalVista Pharma

Syndax Pharmaceuticals

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Rises On Gene Editing Therapy Pact With Vertex: CRISPR announced an amended collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) with respect to CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease and transfusion-dependent beta-thalassemia.

Why Crispr, KalVista And Syndax Are Moving Today

- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia

CRISPR Therapeutics stock reached a 52-week high of $220.20 in Jan 2021 and has since fallen significantly down to $114.39 as of Apr 12, 2021.

CRISPR Therapeutics: A Speculative Play On The Future Of Medicine

Editas Medicine

Intellia Therapeutics

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

CRISPR Therapeutics AG (CRSP) Presents at 20th Annual Needham Virtual Healthcare Conference (Transcript)

ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company's allogeneic chimeric antigen receptor T cell (CAR-T) program at the American Association for Cancer Research (AACR) Annual Meeting 2021. The data, presented today in an e-poster session entitled, CD70 knockout: A novel approach to augment CAR-T cell function, found that the generation of CAR-T cells including knockout of the CD70 show improved properties including potency and persistence over CAR T cells where the CD70 gene remains intact.

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

AbbVie

ACADIA Pharma

Alexion Pharma

AstraZeneca

Biogen

BioNTech SE

Illumina

Kadmon Hlds

Moderna

Pfizer

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

Beam Therapeutics

Cellectis SA

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

Last month, we talked about why investors may want to wait for better levels to enter into the CRSP stock. Since then, the stock has seen a correction of over 28%.

What To Expect From CRISPR Stock After A 14% Drop In 10 Days?

Proto Labs

These companies may represent the future, but their stocks are getting pummeled in the present.

2 Cathie Wood Stocks That Are 40% Off

Is CRISPR Therapeutics Stock Poised to Soar Nearly 30%?

Gene editing has the potential to revolutionize medicine. With CRISPR Therapeutics leading the way, CRSP stock should benefit.

CRISPR Therapeutics Stock Looks Like a Long-Term Biotech Winner

CRISPR Therapeutics AG's (CRSP) CEO Samarth Kulkarni Presents At 33rd Annual ROTH Conference (Transcript)

Teladoc

Tesla's great, but these Cathie Wood favorites have even better growth prospects.

2 Stocks Cathie Wood Loves That Should Be Bigger Winners Than Tesla

With possibly the worst of the novel coronavirus pandemic over, on the surface CRSP stock seems to be a worthwhile rebound pick. However, the technical outlook suggests otherwise.

CRISPR Therapeutics Is a Falling Knife You Don't Want to Catch

ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10 to 15 and May 17 to 21, 2021.

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

bluebird bio

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today appeared first on InvestorPlace.

Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today

Crispr Therapeutics AG's (CRSP) CEO Samarth Kulkarni Presents at Barclays Global Healthcare Conference 2017 (Transcript)

Crispr Therapeutics offers one of the next big technologies and today shares of CRSP stock afford investors access to growth at a discount. The post Why CRSP Stock Is a Less Dicey Risk Asset Today appeared first on InvestorPlace.

News for CRISPR Therapeutics Stock (CRSP)